LUGANO, Switzerland, September 25, 2014 /PRNewswire/ --
Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014.
Cancer anorexia-cachexia syndrome (CACS), characterized by decreased body weight, mainly lean body mass (LBM), is a common, poorly-understood and debilitating condition in patients with cancer, that frequently occurs in patients with advanced NSCLC, for which existing treatment approaches are limited.
The data will be presented at a session, "Supportive and Palliative Care," by the principal investigator in the study, at a session from 14.00 to 15.45 CET on Saturday September 27th in the Pamplona room, IFEMA, Madrid.
Helsinn will host a press conference at 18.00 CET, September 27th, at the IFEMA to discuss the data and broader issues around the treatment of cancer-anorexia-cachexia in non-small cell lung cancer.
Helsinn's Chief Executive Officer, Mr. Riccardo Braglia, commented: "Helsinn is pleased that data from these pivotal trials are to be presented at ESMO for the treatment of Cancer Anorexia-Cachexia for patients with non-small cell lung cancer.
"Helsinn believes anamorelin may offer the potential for a new approach to treating the symptoms of this multifactorial clinical condition.Cancer Anorexia-Cachexia is a debilitating condition which is distressing for patients and caregivers for whom getting the most out of every day is crucial. We are looking forward to participating in a discussion with some of the world's most eminent cancer specialists about how to move forward towards helping people suffering with this condition."
About the Helsinn Group
Helsinn is a family run, privately owned pharmaceutical group focused on building quality cancer care with a large portfolio of products. Founded in 1976 with headquarters in Lugano, Switzerland, Helsinn also has operating subsidiaries in Ireland, the USA and a representative office in China. Helsinn's business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in the therapeutic area of cancer care.
Helsinn Group in-licenses early-to-late stage new chemical entities, completing their development by performing pre-clinical/clinical studies as well as associated manufacturing activities. Helsinn then prepares necessary regulatory filings in order to achieve marketing approvals worldwide. Helsinn's products are out-licensed to its global network of marketing and commercial partners that have been selected for their local market knowledge. Helsinn supports these partners by providing a full range of product and scientific management services, including commercial, regulatory, and medical marketing advice. Helsinn has built a large product portfolio of cancer care products with the alliance of over 65 global partners. In March 2013, Helsinn established a new commercial organization within its subsidiary, Helsinn Therapeutics (U.S.), Inc., in order to conduct direct sales and marketing activities within the U.S. market. Helsinn's products are manufactured according to the highest quality, safety, and environmental standards at Helsinn's GMP facilities in Switzerland and Ireland from where they are then supplied worldwide to customers. Further information on Helsinn Group is available at http://www.helsinn.com
Further information on Helsinn Group is available at http://www.helsinn.com
For more information, please contact:
Head of Communication & Press Office
For media/external inquiries
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Matthew Neal / Laura Thornton
SOURCE Helsinn SA